Clinical trial
A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.
NCT03483116 is registered in ClinicalTrials.gov with Murdoch Childrens Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.
- Lead sponsor
- Murdoch Childrens Research Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 15, 2018
- Completion date
- January 27, 2020
- Enrollment
- 711 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.